Version history

{
  "session_id": "sess_SDA-2026-04-13-gap-pubmed-20260410-145358-185db2c8_20260414-005137",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "synthesize",
  "content": "\n\n```json\n{\n  \"ranked_hypotheses\": [\n    {\n      \"rank\": 1,\n      \"title\": \"APOE Proteolytic Cleavage Suppression and Toxic N-terminal Fragment Reduction\",\n      \"mechanism\": \"R136S stabilizes native APOE structure, reducing proteolytic cleavage that generates toxic N-terminal fragments driving tau pathology and neuronal apoptosis, with homozygous expression achieving near-complete fragment suppression.\",\n      \"target_gene\": \"APOE\",\n      \"confidence_score\": 0.85,\n      \"novelty_score\": 0.70,\n      \"feasibility_score\": 0.85,\n      \"impact_score\": 0.90,\n      \"composite_score\": 0.835,\n      \"testable_prediction\": \"Measure N-terminal fragment levels via Western blot in homozygous vs heterozygous R136S iPSC-derived neurons/microglia under APOE4 background; predict >90% reduction in homozygotes vs ~40% in heterozygotes.\",\n      \"skeptic_concern\": \"Requires validation that proteolytic cleavage rates differ between R136S and wild-type APOE4 in human brain-relevant cell types.\"\n    },\n    {\n      \"rank\": 2,\n      \"title\": \"Conformational Stabilization of APOE N-terminal Domain Modulating Protein-Protein Interactions\",\n      \"mechanism\": \"R136S substitution stabilizes the APOE N-terminal lipid-free conformation, altering binding interfaces for LDL receptor family members and heparin in a gene dosage-dependent manner that differentially modulates tau uptake and clearance.\",\n      \"target_gene\": \"APOE\",\n      \"confidence_score\": 0.65,\n      \"novelty_score\": 0.55,\n      \"feasibility_score\": 0.70,\n      \"impact_score\": 0.75,\n      \"composite_score\": 0.665,\n      \"testable_prediction\": \"Quantify LDL receptor binding affinity and heparin precipitation differences between homozygous, heterozygous R136S, and APOE4; predict sigmoidal dose-response in receptor-mediated uptake of tau seeds.\",\n      \"skeptic_concern\": \"Does not directly explain why partial protection occurs at heterozygous dosage without invoking arbitrary threshold effects.\"\n    },\n    {\n      \"rank\": 3,\n      \"title\": \"Threshold-Dependent ABCA1-Mediated Lipid Efflux and LXRα Activation\",\n      \"mechanism\": \"R136S enhances ABCA1-dependent cholesterol efflux to achieve a critical mass of lipidated APOE that activates LXRα signaling, suppressing SREBP2-mediated inflammation; heterozygous expression produces insufficient lipidated APOE for full threshold activation.\",\n      \"target_gene\": \"ABCA1\",\n      \"confidence_score\": 0.50,\n      \"novelty_score\": 0.65,\n      \"feasibility_score\": 0.50,\n      \"impact_score\": 0.60,\n      \"composite_score\": 0.55,\n      \"testable_prediction\": \"Measure LXR target gene expression (ABCA1, APOE) and cholesterol levels in homozygous vs heterozygous R136S astrocytes; predict non-linear dose-response at LXR activation threshold.\",\n      \"skeptic_concern\": \"LXR agonists have failed clinically due to adverse effects; the 'therapeutic threshold' is unspecified and assumed rather than mechanistically grounded.\"\n    }\n  ],\n  \"consensus_points\": [\n    \"R136S mechanistically acts by enhancing APOE lipidation and structural stability\",\n    \"Gene dosage effect implies a non-linear (likely threshold or sigmoidal) biological response\",\n    \"The protective effect is downstream of APOE structure/function modulation\"\n  ],\n  \"dissent_points\": [\n    \"Whether LXR pathway activation is viable given clinical failure of direct LXR agonists (Skeptic vs Theorist); whether proteolytic cleavage is primary mechanism or secondary consequence (Expert vs Theorist)\"\n  ],\n  \"debate_summary\": \"The debate converged on a structural stabilization mechanism for R136S, with the Expert ranking APOE proteolytic cleavage suppression highest for translational potential due to direct measurement feasibility, while the Skeptic effectively challenged the Theorist's LXR-dependent hypothesis by highlighting clinical failure of LXR agonists and unspecified threshold assumptions. The gene dosage effect most parsimoniously reflects a dose-dependent reduction in toxic fragment generation or non-linear signaling threshold activation.\"\n}\n```",
  "tokens_used": "1009"
}